Latest Period
Q1 2026
Security Snapshot
enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW) Institutional Ownership
CUSIP: 29286M113
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
11
Shares (Excl. Options)
5,053,795
Price
$2.53
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / *W EXP 10/31/202
- Symbol
- ENGNW on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 5,053,795
- Total 13F value
- $12,919,892
- Portfolio coverage rank
- 0%
- Share change
- +208,437
- Value change
- +$322,528
- Number of holders
- 11
- SEC-reported price per share
- $2.30
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
1 identity field
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ENGNW - enGene Therapeutics Inc. - *W EXP 10/31/202 is tracked under CUSIP 29286M113.
- 11 institutions reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 14 to 11 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $13,909,444 to $12,919,892.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 11 institutions filings for Q1 2026.
Security key
29286M113
Latest holder period
Q1 2026
13F holders
11
13D/G owners
0
CIK / CUSIP context first
Open Q1 2026 holders
ENGNW full holder history
enGene Therapeutics Inc. SEC filings
enGene Therapeutics Inc. company facts
enGene Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29286M113:
As of 31 Mar 2026, 11 institutional investors reported holding 5,053,795 shares of enGene Therapeutics Inc. - *W EXP 10/31/202 (ENGNW).
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 5,053,795 | $12,919,892 | +$322,528 | $2.53 | 11 |
| 2025 Q4 | 4,845,358 | $13,909,444 | +$1,124,531 | $2.96 | 14 |
| 2025 Q3 | 4,578,477 | $3,292,332 | -$129,118 | $0.71 | 17 |
| 2025 Q2 | 4,761,181 | $3,703,243 | -$1,778 | $0.82 | 15 |
| 2025 Q1 | 4,763,349 | $2,912,652 | -$3,216 | $0.60 | 14 |
| 2024 Q4 | 4,762,265 | $4,024,339 | -$399,359 | $0.84 | 15 |
| 2024 Q3 | 5,235,834 | $9,204,349 | -$41,253 | $1.95 | 14 |
| 2024 Q2 | 4,761,806 | $5,930,500 | -$1,082,003 | $1.19 | 14 |
| 2024 Q1 | 5,502,863 | $28,624,959 | +$9,669,204 | $5.20 | 16 |
| 2023 Q4 | 4,440,160 | $3,691,565 | +$3,287,750 | $0.85 | 21 |